Parkinson's Disease Research Today is a free monthly online journal that collates and summarizes the latest research about Parkinson's Disease, including details on symptoms, treatment, genetics, medication.

Volume 4 (2007), Issue 4 (April)

1. Initial clinical experience with [123I]ioflupane scintigraphy in movement disorders.
   Clin Radiol, 62(5): 463-71. [Abstract] [Full-text]
2. Variants in the LRRK1 gene and susceptibility to Parkinson's disease in Norway.
   Neurosci Lett, 416(3): 299-301. [Abstract] [Full-text]
3. The effects of levodopa use on diffusion coefficients in various brain regions in Parkinson's disease.
   Neurosci Lett, 416(3): 294-8. [Abstract] [Full-text]
4. Tumor necrosis factor-alpha promoter polymorphism is associated with the risk of Parkinson's disease.
   Am J Med Genet B Neuropsychiatr Genet, 144(3): 300-4. [Abstract] [Full-text]
5. Cyclooxygenase-2 polymorphisms in Parkinson's disease.
   Am J Med Genet B Neuropsychiatr Genet, 144(3): 367-9. [Abstract] [Full-text]
6. Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease.
   Neurology, 68(14): 1108-15. [Abstract] [Full-text]
7. Evaluation of LRRK2 G2019S penetrance: relevance for genetic counseling in Parkinson disease.
   Neurology, 68(14): 1141-3. [Abstract] [Full-text]
8. Anti-beta2-glycoprotein I in Sjogren's syndrome is associated with parkinsonism.
   Clin Rheumatol, 26(5): 743-7. [Abstract] [Full-text]
9. Safety and efficacy of newly formulated selegiline orally disintegrating tablets as an adjunct to levodopa in the management of 'off' episodes in patients with Parkinson's disease.
   Curr Med Res Opin, 23(4): 741-50. [Abstract] [Full-text]
10. Combined x-ray and magnetic resonance imaging facility: application to image-guided stereotactic and functional neurosurgery.
    Neurosurgery, 60(4): 352-60; discussion 360-1. [Abstract] [Full-text]
11. Comparison of two techniques to postoperatively localize the electrode contacts used for subthalamic nucleus stimulation.
    Neurosurgery, 60(4): 285-92; discussion 292-4. [Abstract] [Full-text]
12. Dual microelectrode technique for deep brain stereotactic surgery in humans.
    Neurosurgery, 60(4): 277-83; discussion 283-4. [Abstract] [Full-text]
13. Independent occurrence of I2020T mutation in the kinase domain of the leucine rich repeat kinase 2 gene in Japanese and German Parkinson's disease families.
    Neurosci Lett, 417(1): 21-3. [Abstract] [Full-text]
14. Parkinson's disease shows perceptuomotor asymmetry unrelated to motor symptoms.
    Neurosci Lett, 417(1): 10-5. [Abstract] [Full-text]
15. Consumption of dairy products and risk of Parkinson's disease.
    Am J Epidemiol, 165(9): 998-1006. [Abstract] [Full-text]
16. Pathological gambling after bilateral subthalamic nucleus stimulation in Parkinson disease.
    J Neurol Neurosurg Psychiatry, 78(5): 517-9. [Abstract] [Full-text]
17. A multicentre longitudinal observational study of changes in self reported health status in people with Parkinson's disease left untreated at diagnosis.
    J Neurol Neurosurg Psychiatry, 78(5): 465-9. [Abstract] [Full-text]
18. Improvement of gait by chronic, high doses of methylphenidate in patients with advanced Parkinson's disease.
    J Neurol Neurosurg Psychiatry, 78(5): 470-5. [Abstract] [Full-text]
19. Insomnia in Parkinson's disease: frequency and progression over time.
    J Neurol Neurosurg Psychiatry, 78(5): 476-9. [Abstract] [Full-text]
20. Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study.
    Neurology, 68(16): 1262-7. [Abstract] [Full-text]
21. Brain serotonin transporter binding in non-depressed patients with Parkinson's disease.
    Eur J Neurol, 14(5): 523-8. [Abstract] [Full-text]
22. Quantification of nicotinic acetylcholine receptors in Parkinson's disease with (123)I-5IA SPECT.
    J Neurol Sci, 256(1): 52-60. [Abstract] [Full-text]
23. Poly (ADP-ribose) polymerase-1 (PARP-1) genetic variants are protective against Parkinson's disease.
    J Neurol Sci, 256(1): 68-70. [Abstract] [Full-text]
24. An orally active catalytic metalloporphyrin protects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity in vivo.
    J Neurosci, 27(16): 4326-33. [Abstract] [Full-text]
25. MAPK-pathway activity, Lrrk2 G2019S, and Parkinson's disease.
    J Neurosci Res, 85(6): 1288-94. [Abstract] [Full-text]
26. Compensatory cortical mechanisms in Parkinson's disease evidenced with fMRI during the performance of pre-learned sequential movements.
    Brain Res, 1147: 265-71. [Abstract] [Full-text]
27. Role of heparin binding growth factors in nigrostriatal dopamine system development and Parkinson's disease.
    Brain Res, 1147: 77-88. [Abstract] [Full-text]
28. Autoantibodies to alpha-synuclein in inherited Parkinson's disease.
    J Neurochem, 101(3): 749-56. [Abstract] [Full-text]
29. Defective temporal discrimination of passive movements in Parkinson's disease.
    Neurosci Lett, 417(3): 312-5. [Abstract] [Full-text]
30. Phosphorylation of Parkin by the cyclin-dependent kinase 5 at the linker region modulates its ubiquitin-ligase activity and aggregation.
    J Biol Chem, 282(17): 12842-50. [Abstract] [Full-text]
31. Quetiapine for agitation or psychosis in patients with dementia and parkinsonism.
    Neurology, 68(17): 1356-63. [Abstract] [Full-text]
32. Is DBS-STN appropriate to treat severe Parkinson disease in an elderly population?
    Neurology, 68(17): 1345-55. [Abstract] [Full-text]
33. Effects of an extended version of the lee silverman voice treatment on voice and speech in Parkinson's disease.
    Am J Speech Lang Pathol, 16(2): 95-107. [Abstract] [Full-text]
34. Calpain-cleavage of alpha-synuclein: connecting proteolytic processing to disease-linked aggregation.
    Am J Pathol, 170(5): 1725-38. [Abstract] [Full-text]
35. ELISA reveals a difference in the structure of substantia nigra ferritin in Parkinson's disease and incidental Lewy body compared to control.
    Parkinsonism Relat Disord, 13(4): 214-8. [Abstract] [Full-text]
36. The effect of cigarette smoking, tea, and coffee consumption on the progression of Parkinson's disease.
    Parkinsonism Relat Disord, 13(4): 243-5. [Abstract] [Full-text]
37. Clinical relevance of rehabilitation programs for patients with idiopathic Parkinson syndrome. II: Symptom-specific therapeutic approaches.
    Parkinsonism Relat Disord, 13(4): 203-13. [Abstract] [Full-text]
38. Clinical relevance of rehabilitation programs for Parkinson's disease. I: Non-symptom-specific therapeutic approaches.
    Parkinsonism Relat Disord, 13(4): 195-202. [Abstract] [Full-text]
39. Postsynaptic 5-HT1A receptor stimulation increases motor activity in the 6-hydroxydopamine-lesioned rat: implications for treating Parkinson's disease.
    Psychopharmacology (Berl), 192(1): 49-59. [Abstract] [Full-text]
40. Expanding insights on the involvement of endoplasmic reticulum stress in Parkinson's disease.
    Antioxid Redox Signal, 9(5): 553-61. [Abstract] [Full-text]
41. Mangiferin protects against 1-methyl-4-phenylpyridinium toxicity mediated by oxidative stress in N2A cells.
    Neurosci Lett, 418(2): 159-64. [Abstract] [Full-text]
42. Association of GST M1 null polymorphism with Parkinson's disease in a Chilean population with a strong Amerindian genetic component.
    Neurosci Lett, 418(2): 181-5. [Abstract] [Full-text]
43. Advantages and limitations of the equine disease, pituitary pars intermedia dysfunction as a model of spontaneous dopaminergic neurodegenerative disease.
    Ageing Res Rev, 6(1): 54-63. [Abstract] [Full-text]
44. Frequency-dependent distribution of local field potential activity within the subthalamic nucleus in Parkinson's disease.
    Exp Neurol, 205(1): 287-91. [Abstract] [Full-text]
45. Excessive synchronization of basal ganglia neurons at 20 Hz slows movement in Parkinson's disease.
    Exp Neurol, 205(1): 214-21. [Abstract] [Full-text]

© 2004-2008 Parkinson's Disease Research Today. All Rights Reserved.